Royalty Pharma (RPRX) Gains from Investment Securities (2020 - 2026)

Royalty Pharma has reported Gains from Investment Securities for 7 years, with the latest figure at $3.7 million in Q1 2026.

• Quarterly Gains from Investment Securities fell 72.22% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 62.42% YoY) and the FY2025 annual result came in at $13.4 million, changed 0.0% from the prior year.
• Gains from Investment Securities advanced to $3.7 million in Q1 2026 per RPRX's latest filing, from $900000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $20.7 million in Q1 2022 and troughed at $313000.0 in Q3 2023.
• A 5-year average of $7.0 million and a median of $5.8 million in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities tumbled 94.62% in 2023, then surged 80.0% in 2025.
• Over 5 years, Gains from Investment Securities stood at $5.8 million in 2022, then tumbled by 94.63% to $313000.0 in 2023, then soared by 59.74% to $500000.0 in 2024, then soared by 80.0% to $900000.0 in 2025, then soared by 313.56% to $3.7 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $3.7 million, $900000.0, and $600000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.